Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders

The summary for the Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders: - The purpose of this RFA is to support pilot clinical studies of medications for investigation as possible treatments for Substance Related Disorders. Because the purpose of this RFA is to support pilot studies, preliminary studies are not required. - The National Institute on Drug Abuse intends to commit approximately $4 million dollars in FY 2006 to fund 10-12 new grants in response to this RFA. - This RFA will use the National Institutes of Health (NIH) research project grant (R01) award mechanism with the following modifications: An applicant may request a project period of up to 3 years, and direct costs may not exceed $250,000 per year. - Eligible organizations include for-profit, not-for-profit, public and private institutions, units of state and local governments, eligible agencies of the federal Government, domestic or foreign institutions/organizations. - Eligible principal investigators include any individual with the skills, knowledge and resources necessary to carry out the proposed research. Young investigators, or investigators new to the field of drug abuse research, are particularly encouraged to respond to this RFA. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. - Applicants may submit more than one application, provided they are scientifically distinct. - See Section IV.1 for application materials. - Telecommunications for the hearing impaired is available at: TTY 301-451-0088

Federal Grant Title:	Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-06-002
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Jan 24, 2006
Posted Date:	Aug 19, 2005
Creation Date:	Aug 19, 2005
Archive Date:	Feb 23, 2006
Total Program Funding:	$4,000,000
Maximum Federal Grant Award:	$250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Public and State controlled institutions of higher education Private institutions of higher education State governments County governments City or township governments Special district governments Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...